Stockscreener 앱 받기
7.85
0.00%
0.00
시장 영업 전:
7.79
-0.06
-0.76%
전일 마감가:
$7.85
열려 있는:
$7.8
하루 거래량:
3.07M
Relative Volume:
1.68
시가총액:
$182.83M
수익:
-
순이익/손실:
$-30.04M
주가수익비율:
-4.9684
EPS:
-1.58
순현금흐름:
$-27.38M
1주 성능:
+184.42%
1개월 성능:
+300.51%
6개월 성능:
+426.85%
1년 성능:
+191.82%
1일 변동 폭
$7.74
$7.87
1주일 범위
$2.7575
$8.20
52주 변동 폭
$0.8301
$8.20
Regulus Therapeutics Inc Stock (RGLS) Company Profile
명칭
Regulus Therapeutics Inc
전화
858-202-6300
주소
4224 CAMPUS POINT COURT, SAN DIEGO, CA
RGLS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RGLS
Regulus Therapeutics Inc
|
7.85 | 182.83M | 0 | -30.04M | -27.38M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-27 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-08-02 | 개시 | Oppenheimer | Outperform |
| 2024-03-18 | 개시 | Leerink Partners | Outperform |
| 2018-03-28 | 개시 | B. Riley FBR, Inc. | Neutral |
| 2018-01-05 | 개시 | Leerink Partners | Outperform |
| 2017-06-13 | 재확인 | Chardan Capital Markets | Buy |
| 2017-03-06 | 재확인 | Wedbush | Outperform |
| 2017-01-30 | 다운그레이드 | Needham | Buy → Hold |
| 2017-01-30 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2016-12-07 | 재확인 | Chardan Capital Markets | Buy |
| 2016-11-02 | 재확인 | Needham | Buy |
| 2016-07-25 | 재확인 | Chardan Capital Markets | Buy |
| 2016-06-28 | 재확인 | Chardan Capital Markets | Buy |
| 2016-06-28 | 재확인 | FBR Capital | Outperform |
| 2016-06-28 | 재확인 | Needham | Buy |
| 2016-06-07 | 재확인 | Chardan Capital Markets | Buy |
| 2016-04-13 | 개시 | Chardan Capital Markets | Buy |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-06-09 | 개시 | Guggenheim | Buy |
| 2015-04-21 | 재개 | FBR Capital | Outperform |
| 2014-11-24 | 개시 | Deutsche Bank | Buy |
| 2014-08-07 | 재확인 | FBR Capital | Outperform |
| 2013-08-14 | 재확인 | Needham | Buy |
모두보기
Regulus Therapeutics Inc 주식(RGLS)의 최신 뉴스
Novartis to buy Regulus Therapeutics for as much as $1.7 billion - MSN
REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc.RGLS - Business Wire
Novartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion Deal - GuruFocus
Regulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From Novartis - MSN
Taxation With Representation: Goodwin, Haynes Boone - Law360
Novartis to acquire San Diego-based Regulus in deal worth up to $1.7B - San Diego Union-Tribune
This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga
Regulus Therapeutics (RGLS) Downgraded by Wells Fargo | RGLS Sto - GuruFocus
Novartis Acquires Regulus Therapeutics for $800 Million - GuruFocus
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (NasdaqKRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Coeptis Therapeutics Holdings, Inc. (Nasdaq – COEP), Pacific Premier Bancor - Morningstar
Regulus CVR may be worth $3-$4 a share in Novartis dealanalyst - Seeking Alpha
New $1.7b Novartis acquisition to advance novel microRNA inhibitor - marketscreener.com
Switzerland: Novartis acquires Regulus Therapeutics for up to US$1.7bn - Investors in Healthcare
Leerink Downgrades Regulus Therapeutics to Market Perform From Outperform, Adjusts Price Target to $7 From $6 - marketscreener.com
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead - MSN
Novartis to acquire US-based Regulus Therapeutics for $1.7bn - World Pharmaceutical Frontiers
Novartis to Acquire Regulus Therapeutics in $1.7 Billion Deal - GuruFocus
Regulus (RGLS) Surges on Acquisition by Novartis for $1.7 Billion - GuruFocus
Regulus (RGLS) Downgraded Following Acquisition Agreement | RGLS Stock News - GuruFocus
Regulus (RGLS) Downgraded After Acquisition Agreement with Novar - GuruFocus
Regulus Therapeutics Inc (RGLS): Shares Soar 137% on Acquisition News - Wealth Daily
Novartis Gains Further Renal Territory With Regulus Acquisition - insights.citeline.com
Regulus Therapeutics Acquisition By Novartis Due To Key Farabursen Advancements (RGLS) - Seeking Alpha
Regulus Therapeutics stock soars on acquisition deal with Novartis By Investing.com - Investing.com Nigeria
Novartis Buys Regulus, Boosting Biotech Shares Significantly - Finimize
Wells Fargo Downgrades Regulus Therapeutics to Equalweight From Overweight, $9 Price Target - marketscreener.com
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc.RGLS - PR Newswire
India’s Competition Commission Clears J&K Bank in Antitrust Case - PYMNTS.com
Top Midday Gainers - marketscreener.com
Novartis to Acquire Regulus Therapeutics in $1.7 Billion Deal, Sending Stock Soaring - RagingBull
Novartis to buy Regulus Therapeutics for up to $1.7 billion - MSN
Novartis to acquire Regulus in deal for kidney disease drug - BioPharma Dive
Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher - Benzinga
Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal - Reuters
Novartis to Acquire Regulus Therapeutics in Potential $1.7B Deal - Contract Pharma
Generac, Regulus Therapeutics, Garmin - TradingView
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million - Benzinga
Regulus Therapeutics' stock price doubles on Novartis's buyout offer - TradingView
Regulus (RGLS) Downgraded Amid Acquisition Offer by Novartis | R - GuruFocus
Latham & Watkins Advises Regulus Therapeutics in Acquisition by Novartis AG - Latham & Watkins LLP
Swiss pharma giant Novartis to acquire San Diego biotech Regulus in $1.7B deal - Axios
Biotech Stock Soars Over 100% On Premarket Following Acquisition Announcement - The Globe and Mail
Novartis to acquire Regulus Therapeutics for up to $1.7 billion - PharmaLive
Regulus Announces Merger Agreement with Novartis - TipRanks
RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to Shareholders - The Joplin Globe
Regulus Therapeutics stock soars on acquisition deal with Novartis - Investing.com
Regulus Therapeutics Upon Termination Of Merger Deal Under Some Circumstances, Co To Pay Parent Termination Fee Of $27.3 Million - TradingView
Novartis (NVS) to Acquire Regulus Therapeutics for $0.8B - GuruFocus
Novartis (NVS) to Acquire Regulus Therapeutics in $0.8B Deal | N - GuruFocus
Novartis to Acquire Regulus in $1.7 Billion Deal - WSJ
Novartis to Buy Regulus Therapeutics for as Much as $1.7 Billion (NVS, RGLS) - Bloomberg.com
Regulus Therapeutics Inc (RGLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.47%
2.63%
자본화:
|
볼륨(24시간):